First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation.

Baldini C, Verlingue L, Goldschmidt V, Doger de Spéville B, Lostes J, Italiano A, Cousin S, Falchook GS, Necchi A, Reig Torras O, Fontana E, Carter L, Rodon Ahnert J, Brown JR, DeMars LR, Josephs K, Dickson A, Xu C, Bader J, Campbell C, Sharma R, McKean M

Impact of Age, Sex, and Race on Primary Aldosteronism Test Interpretations.

Newman AJ, Tsai LC, Abel EE, Ferrebus A, Chan JM, Mahrokhian S, Hanna I, Foote K, Tsai CH, Parisien-La Salle S, Brown JM, Vaidya A

Determinants of respiratory tract aerosol generation in a diverse clinical population: an observational study.

Nava GW, Szczepanska A, Ng L, Khan S, Hamilton F, Scott R, Mahmud U, AERATOR group, Saralaya D, Maskell N, Reid JP, Bzdek BR, Dodd JW

Implementation of a Spanish-Language, Direct-to-Patient Primary Aldosteronism Testing Program.

Ferrebus A, Tsai LC, Abel EE, Foote K, Newman AJ, Parisien-La Salle S, Tsai CH, Vaidya A, Brown JM

Developing robust systems for Track 2 MAID in Canada: A qualitative study.

Pesut B, Thorne S, Brad-Richards L, Brown J, Campbell J, Hall M, Plewes L, Robertson D, Sharp H, Stajduhar K, Variath C, Wiebe G

Toward a better pan-tumor predictive signature for unleashing precision immuno-oncology.

Brown JR, Sonpavde G

The Impact of Stigma on U.S. Health Care Provider Perceptions, Treatment, and Care of People who May Be Exposed To or Living with HIV.

Brown JA, Boudewyns V, Uhrig JD, Taylor JC, Stryker JE

Choosing between virtual and in-person family physician care: a qualitative study.

Ryan BL, Brown JB, Freeman TR, daSilva M, Wilson H, Ashcroft R, Terry AL

The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy.

Riboni-Verri G, McMurran CE, Mukherjee T, Daruwalla C, Holland J, Gautam R, Chen BS, Cutting E, Qian W, MacManus D, Chard DT, Brown JWL, Coles AJ, Cunniffe NG

Risk factors for silent cerebral infarction in immune-mediated thrombotic thrombocytopenic survivors.

Javed B, Yu J, Brown J, Meade J, Gerber GF, Streiff MB, Kraus P, Merrill S, Pishko AM, Yui J, Naik RP, Brodsky RA, Lin DD, Chaturvedi S